AEON Biopharma, Inc.

AEON Biopharma, Inc. insiders are currently net sellers of AEON stock, showing bearish sentiment over the past 90 days. Total sales of $73.8M outpace purchases of $0, creating a net outflow of $73.8M.

AEON Biopharma, Inc. has 13 active insiders who have filed SEC Form 4 transactions in the past 90 days. Crown Holdings Group, Llc Strathspey (Executive) leads with 1 transactions totaling $73.8M. John Bencich (CHIEF FINANCIAL OFFICER) follows with 1 transactions worth $0. Open-market purchases require insiders to invest their own capital, demonstrating genuine conviction.

The Insider Alignment Score measures the ratio of buying to selling activity on a 0-100 scale. AEON Biopharma, Inc.'s current score of 0/100 indicates bearish insider sentiment. Scores below 40 indicate selling pressure exceeds buying. Insider selling often reflects diversification needs, tax optimization, or estate planning.

The most recent insider transaction occurred on Apr 2, 2026, when Bencich John (CHIEF FINANCIAL OFFICER) acquired 754,717 shares at $0.00 per share for $0. This appears to be a discretionary trade.

Based on SEC Form 4 filings from the past 90 days, AEON insider trading sentiment is currently bearish with an Alignment Score of 0/100. The negative net flow of $73.8M shows more selling than buying. However, 0% of recent transactions are 10b5-1 scheduled trades.

SEC Form 4 is the primary disclosure mechanism for insider trading at publicly traded companies like AEON Biopharma, Inc.. Corporate insiders must file within two business days of any transaction, making it one of the most timely sources of executive sentiment. At AEON, we track all Form 4 filings—currently showing 41 transactions from 13 insiders over 90 days.

A 10b5-1 plan allows AEON Biopharma, Inc. executives to pre-schedule stock sales when they don't possess material non-public information. At AEON, approximately 0% of recent transactions are 10b5-1 trades. Most trading activity at AEON appears discretionary, making insider signals more meaningful.

You can monitor AEON Biopharma, Inc. (AEON) insider trading activity on this page, which updates within hours of new SEC Form 4 filings. We track all 13 active insiders and provide real-time transaction feeds, the Alignment Score, 10b5-1 vs. discretionary breakdowns, and direct links to SEC EDGAR filings.

Our Alignment Score measures the ratio of insider buying to selling on a scale of 0-100. A score above 70 indicates strong bullish sentiment, while below 30 suggests bearish activity. AEON Biopharma, Inc.'s current score of 0/100 indicates bearish sentiment with significant insider selling pressure. This is calculated from $0 in purchases versus $73.8M in sales over 90 days, resulting in a net flow of -$73.8M.

SEC Form 4 filings are mandatory reports that AEON Biopharma, Inc. insiders must submit within 2 business days. Each filing includes the insider's name, relationship, transaction type, shares, and price. Transaction codes: P (purchase), S (sale), A (award), M (option exercise), G (gift). At AEON, the most common type is "A" with 35 occurrences. The most recent Form 4 was filed on Apr 2, 2026 by Bencich John.

Rule 10b5-1 allows corporate insiders to establish pre-scheduled trading plans when they don't possess material non-public information. At AEON Biopharma, Inc., approximately 0% of recent transactions are executed under 10b5-1 plans, while 100% appear to be discretionary trades. The low percentage means most insider activity at AEON represents discretionary decisions with more informational value.